The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others ...

New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya ...

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...

Johnson & Johnson (J&J) and Protagonist Therapeutics’s joint interleukin-23 (IL-23) inhibitor, icotrokinra, has met the primary endpoint in a Phase IIb study in patients with moderately to ...

Sustainable IBD care requires improving access to cost-effective treatments, increasing biosimilar uptake, and implementing multidisciplinary strategies to reduce expenses. Direct costs of IBD ...

The findings were seen to set the stage for a significant new entrant in the psoriasis treatment landscape, which is led by injectable treatments such as AbbVie’s (NYSE: ABBV) Skyrizi (risankizumab) ...

Stelara sales are now dropping as the biosimilar market opens up. Meanwhile, Tremfya could be poised to take its place as the company’s flagship immunology product. The therapy received approval from ...

The approval is only for the 2.5mg tablet. The Food and Drug Administration (FDA) has approved the first generics of Xarelto ® (rivaroxaban) 2.5mg. Xarelto 2.5mg is used, in combination with ...